Strides Arcolab has announced receipt of 2 ANDA approvals for Ondansetron injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml vials).

The product is licensed to Akorn-Strides, LLC, which is a joint venture that was formed in 2004 by Akorn, Inc and Strides Arcolab Ltd.

Arun Kumar, vice chairman and group CEO of Strides Arcolab stated, "These approvals reflect yet another significant milestone for the Akorn-Strides partnership which now has approvals for five sterile injectable products and plans for commercialization are underway".

The company is exporters of branded generic pharmaceutical products. Strides manufacture pharmaceuticals formulations in various dosage forms, including capsules, tablets, liquid injectables and are one of the world's top five manufacturers of softgel capsules. It also has the globally dedicated soft gel facility for hormones. In addition, company undertakes contract research and the manufacturing of specialty chemicals for various multinational companies.